Advertisement
Advertisement

PHIO

PHIO logo

Phio Pharmaceuticals Corp. Common Stock

1.26
USD
Sponsored
+0.05
+4.51%
Mar 25, 15:59 UTC -4
Closed
exchange

Pre-Market

1.28

+0.02
+1.59%

PHIO Earnings Reports

Positive Surprise Ratio

PHIO beat 24 of 30 last estimates.

80%

Next Report

Date of Next Report
May 13, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/
-$0.23
Implied change from Q4 25 (Revenue/ EPS)
--
/
-8.00%
Implied change from Q1 25 (Revenue/ EPS)
--
/
--

Phio Pharmaceuticals Corp. Common Stock earnings per share and revenue

On Mar 05, 2026, PHIO reported earnings of -0.25 USD per share (EPS) for Q4 25, beating the estimate of -0.34 USD, resulting in a 27.05% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.85% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 3 analysts forecast an EPS of -0.23 USD, with revenue projected to reach -- USD, implying an decrease of -8.00% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Talphera, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
logo
Theravance Biopharma, Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
$1.24
Actual
$0.21
Surprise
-83.12%
logo
Relmada Therapeutics, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.14
Actual
-$0.28
Surprise
-103.08%
logo
Context Therapeutics Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.14
Surprise
-29.39%
logo
Avalo Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.49
Actual
-$1.12
Surprise
+24.33%
logo
Journey Medical Corporation Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.04
Surprise
+31.86%
logo
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-
Surprise
-
logo
Achieve Life Sciences, Inc.
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.12%
logo
Pyxis Oncology, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
logo
Fractyl Health, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
$0.15
Surprise
+181.70%
FAQ
For Q4 2025, Phio Pharmaceuticals Corp. Common Stock reported EPS of -$0.25, beating estimates by 27.05%, and revenue of $0.00, 0% as expectations.
The stock price moved down -0.85%, changed from $1.17 before the earnings release to $1.16 the day after.
The next earning report is scheduled for May 13, 2026.
Based on 3 analysts, Phio Pharmaceuticals Corp. Common Stock is expected to report EPS of -$0.23 and revenue of -- for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement